Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Should l Buy ?
Source: PRnewswire
Delisting from Nasdaq: Seelos Therapeutics, Inc. has been notified by the Nasdaq Hearings Panel that its common stock will be delisted due to non-compliance with the minimum stockholder's equity requirement, effective October 16, 2024, when trading will shift to OTCQB.
Company Overview: Seelos is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases, with several late-stage clinical assets targeting conditions like Major Depressive Disorder and amyotrophic lateral sclerosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
